View Cart  

Sponsors Resigned to Trials for Biosimilar Interchangeability, May Limit Pipelines

A A
The FDA appears poised to require clinical trial data from drugmakers seeking biosimilar interchangeability designations, a move that could shrink the number of products that aim to achieve the standard, drugmakers and legal experts say.

To View This Article:

Login

Subscribe To Drug Industry Daily